Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease
Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK
Published in EBioMedicine
Methodology
Open-label Phase 1 pilot study of 3 days oral dasatinib 100 mg plus quercetin 1000 mg with adipose and skin biopsies measuring senescent cell markers
Key Findings
Three days of dasatinib plus quercetin reduced adipose tissue senescent cell burden within 11 days, including decreases in p16-positive cells.
Conclusions
Intermittent senolytic dosing measurably decreases senescent cell burden in humans.
Limitations
Very small open-label pilot with no placebo control, short follow-up, quercetin given with a prescription chemotherapy drug rather than alone.
Supplements Studied
D + Q reduced adipose tissue senescent cell burden within 11 days, with decreases in p16
Outcomes Measured
D + Q reduced adipose tissue senescent cell burden within 11 days, with decreases in p16
Study Details
Access Study
Disclosures
Funding
NIH and foundations
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.